Intermittent Hypoxia Therapy in Cardiac Rehabilitation
Primary Purpose
Cardiovascular Disease, Exercise, Hypoxia
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Intermittent hypoxia therapy
Conventional phase 2 cardiac rehabilitation programme
Sponsored by
About this trial
This is an interventional treatment trial for Cardiovascular Disease focused on measuring cardiovascular disease, rehabilitation, exercise
Eligibility Criteria
Inclusion Criteria:
- Admission to a Phase 2 in-hospital cardiac rehabilitation program because of a recent index event;
- Provision of signed and dated informed consent form;
- Age ≥ 75 years;
- Basic venous blood oxygen saturation (SpO2) level > 93% measured at the fingertip;
- SPPB score < 7;
- New York Heart Association (NYHA) Class I-III.
Exclusion Criteria:
- Inability to give informed consent (diminished understanding or comprehension);
- Age < 75 years;
- SPPB Score ≥ 7;
- NYHA Class IV and/or concomitant i.v. therapy with cardiovascular active drugs;
- Uncontrolled angina pectoris;
- Uncontrolled arterial hypertension;
- Uncontrolled atrial or ventricular arrhythmias;
- Active pericarditis or myocarditis;
- Need of continuous or intermittent O2 therapy;
- Hb < 10 g/dl;
- Severe concomitant non-cardiac diseases such as cancer or any other systemic disease limiting to participate in the study
- Acute inflammatory diseases;
- Acute non-cardiac somatic diseases, or somatic diseases with symptoms of decompensation;
- Currently implanted left ventricular assist device;
- Inability to accept the procedure of breathing via facial mask.
Sites / Locations
- Istituti Clinici Scientifici Maugeri IRCCS
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
IHT group
Conventional group
Arm Description
Intermittent hypoxia therapy on top of the conventional phase 2 in-hospital rehabilitation program
Conventional phase 2 in-hospital rehabilitation program
Outcomes
Primary Outcome Measures
Changes in SPPB score
The Short Physical Performance Battery (SPPB) is a series of physical performance tests used in older persons to assess lower extremity function and mobility.
Score total: minimum 0 (lowest performance), maximum 12 (highest performance). Three subscales (minimum 0, maximum 4 points each one): balance test, gait speed test, chair stand test.
Secondary Outcome Measures
Changes in distance at the 6-min walking test
6-min walking test is a test for functional evaluation based on walking distance performed by the patient in the time window at the individual walking speed. Score in meters: minimum zero, maximum indefinite
Changes in peak exercise oxygen uptake (peak VO2)
Peak VO2 represents the maximal individualized oxygen consumption at the peak effort, evaluated by means of cardiopulmonary exercise testing, expressed by means of ml of oxygen per Kg of body weight per minute.
Changes in basal blood pressure
Expressed by means of mmHg. Indicator of haemodynamic status.
Changes in basal heart rate
Expressed by means of number of beats per minute. Indicator of haemodynamic status.
Changes in EuroQoL score
European Quality of Life score (EuroQoL). Score: from 0 (lowest condition) to 10 (best condition).
Changes in geriatric depression scale
30 items with relative categorization (1 present; 0 absent). Minimum 0 points (absence of depression), maximum 30 point (highest grade of depression).
Changes in minimental state evaluation
Tool for evaluation of cognitive status in older patients. Minimum score 0 (absence of cognitive impairment), maximum 30 (highest grade of cognitive impairment)
Full Information
NCT ID
NCT04034082
First Posted
July 22, 2019
Last Updated
December 14, 2021
Sponsor
Istituti Clinici Scientifici Maugeri SpA
1. Study Identification
Unique Protocol Identification Number
NCT04034082
Brief Title
Intermittent Hypoxia Therapy in Cardiac Rehabilitation
Official Title
Effect of Intermittent Hypoxia Therapy on Functional Capacity in Geriatric Cardiac Patients With Functional Impairment During a Cardiac Rehabilitation Program: a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
February 12, 2019 (Actual)
Primary Completion Date
June 30, 2020 (Actual)
Study Completion Date
October 30, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Istituti Clinici Scientifici Maugeri SpA
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a randomized control pilot study to assess the effect of intermittent hypoxia therapy on functional capacity vs conventional care in old patients with functional impairment admitted to a Phase 2 in-hospital cardiac rehabilitation program.
Detailed Description
Because the improvement of exercise tolerance reduces mortality in elderly patients affected by cardiovascular disease, intermittent hypoxia therapy (IHT) - defined as repeated episodes of hypoxia interspersed with normoxic periods delivered by an ad hoc device - might be a valuable tool to be associated to structured cardiac rehabilitation (CR) interventions.
The present study is a pilot, monocentric, randomized (randomization ratio 1:1), parallel group study to assess the effect of IHT on functional capacity vs conventional care in old patients with functional impairment admitted to a phase 2 in-hospital cardiac rehabilitation program.
The study will enroll cardiac patients of both genders, ≥ 75 years and with a functional impairment assessed by a Short Physical Performance Battery (SPPB) score < 7.
The effect of IHT on functional capacity will be evaluated on top of the conventional multidisciplinary CR intervention, by means of SPPB score variation; variations in quality of life and cognitive status will also be evaluated as secondary goals of the study.
The total amount of IHT sessions per patient will be 10, 1 per day over 2 weeks, the duration of each single procedure will be 45 min and the Hypoxic O2 conc.% will be 14-10. The study was approved by local ethic committee.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Disease, Exercise, Hypoxia
Keywords
cardiovascular disease, rehabilitation, exercise
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IHT group
Arm Type
Experimental
Arm Description
Intermittent hypoxia therapy on top of the conventional phase 2 in-hospital rehabilitation program
Arm Title
Conventional group
Arm Type
Active Comparator
Arm Description
Conventional phase 2 in-hospital rehabilitation program
Intervention Type
Device
Intervention Name(s)
Intermittent hypoxia therapy
Intervention Description
Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
Intervention Type
Other
Intervention Name(s)
Conventional phase 2 cardiac rehabilitation programme
Intervention Description
The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
Primary Outcome Measure Information:
Title
Changes in SPPB score
Description
The Short Physical Performance Battery (SPPB) is a series of physical performance tests used in older persons to assess lower extremity function and mobility.
Score total: minimum 0 (lowest performance), maximum 12 (highest performance). Three subscales (minimum 0, maximum 4 points each one): balance test, gait speed test, chair stand test.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Changes in distance at the 6-min walking test
Description
6-min walking test is a test for functional evaluation based on walking distance performed by the patient in the time window at the individual walking speed. Score in meters: minimum zero, maximum indefinite
Time Frame
30 days
Title
Changes in peak exercise oxygen uptake (peak VO2)
Description
Peak VO2 represents the maximal individualized oxygen consumption at the peak effort, evaluated by means of cardiopulmonary exercise testing, expressed by means of ml of oxygen per Kg of body weight per minute.
Time Frame
30 days
Title
Changes in basal blood pressure
Description
Expressed by means of mmHg. Indicator of haemodynamic status.
Time Frame
30 days
Title
Changes in basal heart rate
Description
Expressed by means of number of beats per minute. Indicator of haemodynamic status.
Time Frame
30 days
Title
Changes in EuroQoL score
Description
European Quality of Life score (EuroQoL). Score: from 0 (lowest condition) to 10 (best condition).
Time Frame
30 days
Title
Changes in geriatric depression scale
Description
30 items with relative categorization (1 present; 0 absent). Minimum 0 points (absence of depression), maximum 30 point (highest grade of depression).
Time Frame
30 days
Title
Changes in minimental state evaluation
Description
Tool for evaluation of cognitive status in older patients. Minimum score 0 (absence of cognitive impairment), maximum 30 (highest grade of cognitive impairment)
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Admission to a Phase 2 in-hospital cardiac rehabilitation program because of a recent index event;
Provision of signed and dated informed consent form;
Age ≥ 75 years;
Basic venous blood oxygen saturation (SpO2) level > 93% measured at the fingertip;
SPPB score < 7;
New York Heart Association (NYHA) Class I-III.
Exclusion Criteria:
Inability to give informed consent (diminished understanding or comprehension);
Age < 75 years;
SPPB Score ≥ 7;
NYHA Class IV and/or concomitant i.v. therapy with cardiovascular active drugs;
Uncontrolled angina pectoris;
Uncontrolled arterial hypertension;
Uncontrolled atrial or ventricular arrhythmias;
Active pericarditis or myocarditis;
Need of continuous or intermittent O2 therapy;
Hb < 10 g/dl;
Severe concomitant non-cardiac diseases such as cancer or any other systemic disease limiting to participate in the study
Acute inflammatory diseases;
Acute non-cardiac somatic diseases, or somatic diseases with symptoms of decompensation;
Currently implanted left ventricular assist device;
Inability to accept the procedure of breathing via facial mask.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roberto Pedretti, MD
Organizational Affiliation
ICS Maugeri care and Research Institute, Pavia, Italy
Official's Role
Study Chair
Facility Information:
Facility Name
Istituti Clinici Scientifici Maugeri IRCCS
City
Pavia
ZIP/Postal Code
27100
Country
Italy
12. IPD Sharing Statement
Learn more about this trial
Intermittent Hypoxia Therapy in Cardiac Rehabilitation
We'll reach out to this number within 24 hrs